Researchers unveiled an intelligent AAV design framework that programs vectors to respond dynamically to tumor‑microenvironment cues, improving targeting and intratumoral penetration. The study details synthetic regulatory elements and capsid modifications that restrict transduction to tumor contexts, addressing long‑standing specificity and safety issues for viral gene delivery. The team demonstrated proof‑of‑concept in preclinical tumor models, reporting enhanced tumor infiltration and reduced off‑target expression. The approach leverages TME‑sensing motifs to gate transgene expression and may be compatible with existing AAV serotypes. Biotech firms developing AAV therapeutics may incorporate these design principles to refine oncology and gene‑therapy pipelines; regulators will scrutinize safety and biodistribution data as tumor‑selective constructs move toward IND filings.